Novartis Ag (NVSEF) Cash from Financing Activities (2009 - 2025)

Novartis Ag has disclosed Cash from Financing Activities across 14 years of filings, most recently posting -$5.2 billion for Q2 2025.

• Cash from Financing Activities for Q2 2025 came in at -$5.2 billion, down 62.91% year-over-year; the trailing twelve-month figure through Jun 2025 was -$17.2 billion (down 278.95% YoY), and the FY2025 annual result was -$14.9 billion, down 26.61% from the prior year.
• Cash from Financing Activities came in at -$5.2 billion for Q2 2025 at Novartis Ag, up from -$8.4 billion in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of -$382.0 million in Q3 2024 to a low of -$11.8 billion in Q4 2022.
• The 5-year median for Cash from Financing Activities is -$3.2 billion (2024), against an average of -$4.6 billion.
• Across the five-year window, Cash from Financing Activities jumped 95.81% in 2023 and plunged 1586.29% in 2024, its largest moves.
• Novartis Ag's Cash from Financing Activities stood at -$11.5 billion in 2021, then fell by 3.18% to -$11.8 billion in 2022, then surged by 95.81% to -$496.0 million in 2023, then slumped by 1586.29% to -$8.4 billion in 2024, then soared by 37.67% to -$5.2 billion in 2025.
• The last three Cash from Financing Activities figures came in at -$5.2 billion (Q2 2025), -$8.4 billion (Q4 2024), and -$382.0 million (Q3 2024), per Business Quant data.